Glycosaminoglycan chain biosynthetic machinery

The glycosaminoglycan (GAG) chain biosynthetic machinery is a coordinated system of Golgi-resident enzymes responsible for the synthesis and modification of complex linear polysaccharides, including heparan sulfate, chondroitin sulfate, and dermatan sulfate [NIH, 2021; Frontiers in Molecular Biosciences, 2021]. This machinery comprises various glycosyltransferases, such as xylosyltransferases and polymerases (e.g., EXT1, EXT2, CHSY1), as well as modifying enzymes like sulfotransferases and epimerases [NIH, 2021; Frontiers in Molecular Biosciences, 2021]. These enzymes work in concert to assemble GAG chains on proteoglycan core proteins, creating structural and functional components of the extracellular matrix and cell surface [NIH, 2019; American Journal of Physiology, 2021]. GAGs play critical roles in cell signaling, growth factor regulation, and tissue morphogenesis [NIH, 2019; NIH, 2014]. Dysregulation of the GAG biosynthetic machinery is implicated in several diseases, including cancer, where altered GAG patterns facilitate tumor growth and metastasis, and viral infections, where GAGs serve as entry receptors [American Journal of Physiology, 2021; MDPI, 2021]. Therapeutic targeting of this machinery involves the use of decoy substrates like Odiparcil or inhibitors like Genistein to modulate GAG production and structure, offering potential treatments for metabolic disorders and oncology [NIH, 2019; NIH, 2014].

Other names

GAG biosynthetic machineryGAG biosynthetic enzymesGAGosomeGlycosaminoglycan biosynthesis pathway

Decoy substrate competition and enzymatic inhibition of glycosaminoglycan chain initiation, elongation, and modification [NIH, 2014; NIH, 2019].